普拉洛芬联合玻璃酸钠治疗中重度干眼症的临床观察

发布时间：2018-05-22 11:27

  本文选题：普拉洛芬 + 玻璃酸钠　； 参考：《中国药房》2016年35期

【摘要】：目的:探讨普拉洛芬联合玻璃酸钠治疗中重度干眼症的有效性和安全性。方法:将180例中重度干眼症患者按随机数字表法分为观察组和对照组,各90例。对照组患者常规采用玻璃酸钠滴眼液,每次1滴,tid,同时采用清洁眼睑、热敷及睑板腺按摩等物理治疗;观察组患者在对照组治疗基础上加用普拉洛芬滴眼液,每次1滴,tid,2周为1个疗程。比较两组患者治疗前后的单眼角膜荧光素染色评分、泪膜破裂时间(BUT)、干眼症状评分、泪液分泌试验Ⅰ(SIT)结果,并据此评价两组患者的临床疗效;同时,观察两组患者的不良反应发生情况。结果:治疗2、4周后,两组患者的单眼角膜荧光素染色评分、干眼症状评分均明显低于治疗前,BUT和SIT均明显长于治疗前,且治疗4周后各指标均明显优于治疗2周后;观察组患者治疗2、4周后各指标均明显优于同期对照组,差异均有统计学意义(P0.05)。观察组患者的有效率为94.44%,明显高于对照组的78.89%,差异有统计学意义(P0.05)。两组患者在用药过程中仅出现不同程度的眼部刺激症状,未出现其他严重的并发症,且眼部刺激症状评分各分数段组间比较,差异均无统计学意义(P0.05)。结论:普拉洛芬联合玻璃酸钠治疗中重度干眼症患者,能明显控制眼表炎症、提高泪膜稳定性,疗效确切,且具有较高的安全性。
[Abstract]:Objective: to investigate the efficacy and safety of Praprofen combined with sodium hyaluronate in the treatment of moderate and severe dry eye disease. Methods: 180 patients with moderate and severe xerophthalmia were randomly divided into observation group (n = 90) and control group (n = 90). The patients in the control group were routinely treated with sodium hyaluronate eye drops, 1 tid at a time, while the patients in the observation group were given physical therapy such as clean eyelid, hot compress and eyelid gland massage, while the patients in the observation group were treated with Praprofen eye drops on the basis of the treatment in the control group. A course of treatment was given for 2 weeks. The results of corneal fluorescein staining, tear film rupture time, dry eye score and tear secretion test 鈪，

本文编号：1921872